The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...

The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine ...

The newly approved prefilled syringe version of Shingrix is expected to simplify administration and supports efforts to ...

GSK (GSK) stock in focus as the U.S. FDA approves a new prefilled syringe presentation of its shingles vaccine, Shingrix.

The syringe removes the need to reconstitute separate vials prior to administration, which simplifies the vaccine administration process for healthcare professionals, GSK said Thursday. The existing ...

This image provided by GlaxoSmithKline shows the company's Shingrix vaccine. On Oct. 20, 2017, the Food and Drug Administration approved the vaccine to prevent painful shingles in people aged 50 ...

GlaxoSmithKline's experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the ...

Lasting protection against shingles for adults over 50 with GSK's RZV vaccine. New data from ZOSTER-049 trial reveals over a decade of high efficacy. Plus, GSK's oral antibiotic, gepotidacin ...

GlaxoSmithKline agent Hz/su (aka GSK 1437173A), a Herpes zoster (shingles) vaccine candidate, met its primary endpoint in a Phase-III trial, the firm said, and is shaping up to be a potential ...

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles vaccine in China, the UK drugmaker said on Thursday, lower than previously ...

GSK GSK0.28%increase; green up pointing triangle expects to further grow sales and earnings after its best-selling shingles vaccine Shingrix and the launch of RSV vaccine Arexvy helped the pharma ...

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.